18 documents found, page 1 of 2
Retinopatia Diabética - Orientações Clínicas 2023
Henriques, José; Pessoa, Bernardete; Figueira, João; Nascimento, João; Coelho, João; Ferreira, André; Rodrigues, Diogo; Gonçalves, Luís; Medeiros, MarcoDocumento: RD-gdl 0010 GER Portugal versão 1.2 Out-2023 (Este Documento esteve em discussão no GER e na SPO até 31 de Outubro de 2023 para recolha de opinião de todos os interessados de forma a melhorar o seu conteúdo e obter o maior consenso possível. A todos os colegas que deram o seu contributo, o grupo de trabalho agradece a colaboração.)
Outcomes of Planed Intravitreal Therapy Interruption due to COVID-19 in Patient...
Castro, Catarina; Coelho, João; Correia, Nuno; Lume, Miguel; Menéres, Pedro; Pessoa, BernardeteINTRODUCTION: Our aim was to evaluate the outcomes of planed intravitreal injection (IVI) interruption in eyes with diabetic macular edema (DME) and the overall impact of COVID-19 in IVI. METHODS: Retrospective analysis of clinical data of eyes with DME undergoing treatment with IVI, that missed an IVI by their doctor’s decision (based on an implemented treatment guideline) due to COVID-19 pandemic, between 19 ...
Systemic and vitreous biomarkers : new insights in diabetic retinopathy
Pessoa, Bernardete; Heitor, João; Coelho, Constança; Leander, Magdalena; Menéres, Pedro; Figueira, João; Meireles, Angelina; Beirão, MeloPurpose: Diabetic retinopathy (DR) is a microvascular inflammatory and neurodegenerative disease. The purpose of this study was to analyze the relationship between DR severity and the levels of potential biomarkers in the serum and/or vitreous. Methods: A prospective, consecutive, controlled, observational study was performed between June 2018 and January 2020. Blood and vitreous samples were collected on the d...
Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response ...
Pessoa, Bernardete; Leite, João; Heitor, João; Coelho, João; Monteiro, Sérgio; Coelho, Constança; Figueira, João; Meireles, AngelinaTo evaluate the role of the vitreous in the management of diabetic macular edema with ranibizumab intravitreal injections in a pro re nata regimen. Prospective study of 50 consecutive eyes with diabetic macular edema treated with ranibizumab and 12 months of follow-up. Primary endpoint: to assess differences between non-vitrectomized and vitrectomized eyes in the number injections needed to control the edema. S...
Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular E...
Pessoa, Bernardete; Malheiro, Luísa; Carneiro, Inês; Monteiro, Sílvia; Coelho, João; Coelho, Constança; Figueira, João; Meireles, AngelinaAim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab. Methods: Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analysed pr...
Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema D...
Marques, Joao Heitor; Abreu, Ana Carolina; Silva, Nisa; Meireles, Angelina; Pessoa, Bernardete; Beirão, JoãoBackground: Cystoid macular edema (CME) due to Irvine-Gass syndrome (IGS) is one of the common causes of painless visual impairment post-cataract extraction. The treatment of recurrent cases remains unstandardized. Objective: To evaluate the effectiveness and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day; ILUVIEN®) in the off-label treatment of recurrent CME due to IGS. Methods: Retrospectiv...
Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular E...
Pessoa, Bernardete; Malheiro, Luisa; Carneiro, Inês; Monteiro, Sílvia; Coelho, João; Coelho, Constança; Figueira, João P; Meireles, AngelinaAim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab. Methods: Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analysed pri...
Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vi...
Pessoa, Bernardete; Marques, Joao Heitor; Leite, João; Silva, Nisa; José, Diana; Coelho, Constança; Figueira, João P; Meireles, Angelina; Beirão, JoãoAim: Diabetic retinopathy staging system and progression predictors are soon to be considered insufficient for ophthalmologic practice. Given the growing evidence of the role of choroidal dysfunction, our purpose was to assess choroidal vascular changes with intravitreal ranibizumab (RBZ) treatment in diabetic macular edema (DME). Methods: This was a prospective longitudinal cohort study. The study included DME...
Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular e...
Pessoa, Bernardete; Malheiro, Luísa; Carneiro, Inês; Monteiro, Sílvia; Coelho, João; Coelho, Constança; Figueira, João; Meireles, AngelinaAim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab. Methods: Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analysed pri...
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediate...
Adams, David; Polydefkis, Michael; González-Duarte, Alejandra; Wixner, Jonas; Kristen, Arnt V.; Schmidt, Hartmut H.; Berk, John L.Background: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods: This multicentre, open-label ex...